After some confusion over the status of its regulatory filing in the EU, Russia’s COVID-19 vaccine, Sputnik V, has finally begun a rolling review at the European Medicines Agency, based on results from laboratory studies and clinical trials in adults.
Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review
‘A Major Step’ Towards Approval, Say Backers
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
More from Vaccines
More from Pink Sheet
• By
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.